SI3697819T1 - Zdravljenje raka jajčnikov z anti-CD47 in anti-PD-L1 - Google Patents

Zdravljenje raka jajčnikov z anti-CD47 in anti-PD-L1

Info

Publication number
SI3697819T1
SI3697819T1 SI201830820T SI201830820T SI3697819T1 SI 3697819 T1 SI3697819 T1 SI 3697819T1 SI 201830820 T SI201830820 T SI 201830820T SI 201830820 T SI201830820 T SI 201830820T SI 3697819 T1 SI3697819 T1 SI 3697819T1
Authority
SI
Slovenia
Prior art keywords
treatment
ovarian cancer
ovarian
cancer
Prior art date
Application number
SI201830820T
Other languages
English (en)
Slovenian (sl)
Inventor
Chris Hidemi Mizufune Takimoto
Jens-Peter Volkmer
Mark Ping Chao
Original Assignee
Forty Seven, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty Seven, Inc. filed Critical Forty Seven, Inc.
Publication of SI3697819T1 publication Critical patent/SI3697819T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI201830820T 2017-10-18 2018-10-18 Zdravljenje raka jajčnikov z anti-CD47 in anti-PD-L1 SI3697819T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574073P 2017-10-18 2017-10-18
PCT/US2018/056442 WO2019079549A1 (en) 2017-10-18 2018-10-18 TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1
EP18807145.0A EP3697819B1 (en) 2017-10-18 2018-10-18 Treatment of ovarian cancer with anti-cd47 and anti-pd-l1

Publications (1)

Publication Number Publication Date
SI3697819T1 true SI3697819T1 (sl) 2023-01-31

Family

ID=64402251

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830820T SI3697819T1 (sl) 2017-10-18 2018-10-18 Zdravljenje raka jajčnikov z anti-CD47 in anti-PD-L1

Country Status (12)

Country Link
US (1) US20210047416A1 (enExample)
EP (2) EP4194470A1 (enExample)
JP (3) JP7308190B2 (enExample)
KR (1) KR20200070341A (enExample)
CN (1) CN111315783A (enExample)
AU (1) AU2018351007B2 (enExample)
CA (1) CA3078430A1 (enExample)
ES (1) ES2938652T3 (enExample)
PL (1) PL3697819T3 (enExample)
PT (1) PT3697819T (enExample)
SI (1) SI3697819T1 (enExample)
WO (1) WO2019079549A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114716552B (zh) 2016-01-11 2024-05-24 四十七公司 人源化、小鼠或嵌合抗cd47单克隆抗体
CN111247172B (zh) 2017-10-18 2023-11-14 四十七公司 基于抗cd47剂的卵巢癌疗法
EP4129336B1 (en) 2018-02-12 2025-05-07 Forty Seven, LLC Anti-cd47 agent-based treatment of cd20-positive cancer
EP3969484A4 (en) * 2019-05-17 2023-07-05 Nanjing GenScript Biotech Co., Ltd. ANTI-CD47/ANTI-PD-L1 MULTIPLE ANTIGEN BINDING PROTEINS AND METHODS OF USE
US11702474B2 (en) 2019-12-17 2023-07-18 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
CN120437288A (zh) * 2019-12-24 2025-08-08 正大天晴药业集团南京顺欣制药有限公司 治疗卵巢癌的药物组合
WO2021170082A1 (zh) * 2020-02-28 2021-09-02 南京圣和药业股份有限公司 抗cd47/抗pd-l1抗体及其应用
CN116670289A (zh) * 2021-01-08 2023-08-29 北京韩美药品有限公司 抗pd-l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616010T3 (es) 2010-05-14 2017-06-09 The Board Of Trustees Of The Leland Stanford Junior University Anticuerpos monoclonales humanizados y quiméricos a CD47
AU2014238105B2 (en) 2013-03-15 2018-11-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-CD47 agents
CA2961774C (en) * 2014-10-07 2023-05-23 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2017019767A1 (en) * 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
CA2998644A1 (en) * 2015-09-18 2017-03-23 Arch Oncology, Inc. Therapeutic cd47 antibodies
US20190290759A1 (en) * 2015-12-28 2019-09-26 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
WO2017127707A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with combinations of immunoregulatory agents

Also Published As

Publication number Publication date
JP7474827B2 (ja) 2024-04-25
PT3697819T (pt) 2023-02-20
ES2938652T3 (es) 2023-04-13
EP4194470A1 (en) 2023-06-14
JP2023014162A (ja) 2023-01-26
US20210047416A1 (en) 2021-02-18
KR20200070341A (ko) 2020-06-17
EP3697819A1 (en) 2020-08-26
AU2018351007B2 (en) 2024-05-16
AU2018351007A1 (en) 2020-05-21
WO2019079549A1 (en) 2019-04-25
CN111315783A (zh) 2020-06-19
EP3697819B1 (en) 2022-11-16
JP2024024121A (ja) 2024-02-21
CA3078430A1 (en) 2019-04-25
JP7308190B2 (ja) 2023-07-13
PL3697819T3 (pl) 2023-03-06
JP2021500336A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
IL275663A (en) Cancer treatment methods
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL263925A (en) Methods of treating ovarian cancer
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
SI3697819T1 (sl) Zdravljenje raka jajčnikov z anti-CD47 in anti-PD-L1
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
IL256025A (en) Methods of diagnosing and treating cancer
IL261959B1 (en) Cancer treatment with tg02
EP3157336A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
IL262342A (en) Cancer treatment methods
ZA201802481B (en) Novel biomarkers and methods of treating cancer
SG11202005163PA (en) Methods of treating cancer
SG10202103525UA (en) Cancer biomarkers and methods of use
IL269123A (en) Methods of treating cancer
IL255541A (en) Cabazitaxel and its use for treating cancer
GB201609402D0 (en) Materials and methods for treating cancer
SG11202002529TA (en) Ovarian cancer biomarker and use thereof
GB201503371D0 (en) Methods of screening and treatment
GB201704287D0 (en) Treatment of cancer
GB201703857D0 (en) Treatment of cancer
GB201702565D0 (en) Treatment of cancer
GB201702139D0 (en) Methods of cancer treatment
AU2016904962A0 (en) Methods of treating cancer and reagents therefor
GB201522615D0 (en) Methods of screening and treatment
GB201505437D0 (en) Methods of screening and treatment